Cigna Announces Value-Based Contracts For Cholesterol Drugs

On May 11, 2016, Cigna announced it had entered into value-based contracts for a new class of drugs to lower cholesterol marketed by the pharmaceutical companies Amgen and Sanofi/Regeneron. The value-based contracts are for Cigna’s commercial insurance businesses. Under these two independent contracts, Amgen agreed to modify the cost of Repatha TM and Sanofi/Regeneron agreed to modify the cost of Praluent® based on how well Cigna members respond to the medications.

Repatha and Praluent are specialty drugs in a new class known as PCSK9 inhibitors; the U.S. Food and Drug Administration approved the two . . .